Wolwo Pharma(SZ:300357) Zheng Quan Zhi Xing·2025-08-22 11:46Core Viewpoint - Iwubio (300357.SZ) reported a strong mid-year performance with double-digit growth in both revenue and profit, driven by its core products and a robust innovation system [1][2][3] Financial Performance - Revenue increased to 484 million yuan, a year-on-year growth of 12.81% - Net profit attributable to shareholders reached 177 million yuan, with a year-on-year increase of 18.61% - Deducting non-recurring gains, net profit grew by 21.97% to 173 million yuan - Gross margin improved to 95.37%, and operating cash flow surged by 96.08% to 200 million yuan [1][3][4] Product Performance - The main product, "Dust Mite Drops," generated sales of 455 million yuan, up 10.51% year-on-year - "Artemisia Pollen Drops" sales reached 21.02 million yuan, a growth of 71.37% - "Skin Prick Test Kit" sales amounted to 6.33 million yuan, increasing by 104.38% [2][3][4] R&D and Innovation - R&D investment accounted for 12.74% of revenue, totaling 61.68 million yuan - The company has 7 products in the pipeline, including "House Dust Mite Membrane" which is in Phase I clinical trials - Iwubio holds 13 valid Chinese invention patents and 7 foreign invention patents [4][5][6] Market Strategy - The company employs an efficient sales model combining academic promotion and commercial distribution - Iwubio is expanding its strategic focus to include stem cell therapy and natural medicines, laying a foundation for long-term growth [6]